On August 16, the pharmaceutical manufacturer Genentech reported a nationwide shortage of the IV formulation of its biologic therapy ACTEMRA. As Genentech reports, the shortage is due to unexpected demand due to its use as a therapeutic for COVID-19 amidst the recent Delta variant surge.
Since that time, IVX Health has experienced supply constraints for not only ACTEMRA IV but also for the subcutaneous formulation of the therapy ACTEMRA SQ. IVX predicts the ACTEMRA shortage to remain at least through the end of the year and potentially into 2022 as well.
At this time, IVX Health cannot guarantee product availability for its existing patients and strongly encourages its referring providers to proactively evaluate alternative therapy options.
As the length of the disruption cannot be predicted, we recommend that providers begin proactively evaluating alternate approaches to their patients’ therapy regimens. Patients should consult their doctor to determine the best approach to any changes in their prescribed therapy regimen.
ITo inquire about a previously scheduled ACTEMRA appointment, please contact your IVX Health local center.
As product availability cannot be guaranteed at this time, IVX is not accepting new ACTEMRA patients.